Summary
Ten anthracyclines, including doxorubicin (DX) and daunorubicin (DNR), and eight analogs with modifications in structure or stereochemistry of the aglycone and/or the aminosugar moiety were simultaneously tested in serial in vitro titration studies against human adenocarcinomas in the human tumor stem cell assay. More than a two-log range in cytotoxicity of the various anthracyclines was observed with the tumors tested. Marked individual differences in sensitivity of specific tumors (breast, lung, peritoneal) were observed for the various analogs. By assessing average effects on survival of tumor colony-forming units (TCFU) in the tumors tested, the three compounds lacking the methoxyl group in position 4 of the aglycone (4-demethoxyDX, 4-demethoxy-4′-epiDX, 4-demethoxyDNR) all proved to be more cytotoxic than their parent compounds. compounds modified in position 4′ of the aminosugar were on average either as toxic (4′ epiDX) or more toxic (4′-deoxyDX and 4′-0-methylDX) to TCFU than the parent compound DX. On average, 11-deoxyDX was less toxic than DX or the other eight anthracyclines tested. The results obtained are also in good general agreement with those previously reported for anthracyclines with human tumors in xenografts or cancer patients. These antitumor results viewed in concert with toxicology studies in normal mice (including evidence of a lack of cardiac toxicity) suggest that 4′ deoxyDX may prove to be a clinically useful anthracycline analog. We also conclude that use of this clinically predicitive in vitro soft agar assay provides a rapid and relatively inexpensive means of simultaneously testing a large number of analogs of a parent compound against a spectrum of human tumors.
Similar content being viewed by others
References
Alberts DS, Chen H-SG, Soehnlen B, Salmon SE, Surwit EA, Young L, Moon TE (1980) In vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. Lancet 2: 340
Alberts DS, Chen H-SG, Salmon SE, Surwit EA, Young L, Moon TE, Meyskens FL (1981) Chemotherapy of ovarian cancer directed by the human tumor stem cell assay. Cancer Chemother Pharmacol (in press)
Arcamone F, Di Marco A, Casazza AM (1978) Chemistry and pharmacology of new antitumor anthracyclines. In: Umezawa H. (ed) Advances in cancer chemotherapy. Japanese Science Society, Tokyo University Park Press, Baltimore, pp 297–312
Benjamin RS, Riggs CE, Bachur NR (1977) Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 37: 1416
Bonfante V, Villani F, Bonadonna G, Veronesi U (1979) Phase I study of 4′-epi-adriamycin (epi-ADM). Proc Am Assoc Cancer Res 20: 172
Casazza AM (1979) Experimental evaluation of anthracycline analogs. Cancer Treat Rep 63: 835
Casazza AM, Di Marco A, Bertazzoli C, Formelli F, Giuliana F, Pratesi G (1978) Antitumor activity, toxicity, and pharmacological properties of 4′-epiadriamycin. In: Siegenthaler W, Luthy R (eds) current chemotherapy. American Society for Microbiology, Washington, pp 1257–2360
Casazza AM, Di Marco A, Bonadonna G, Bonfante V, Bertazzoli C, Bellini O, Pratesi G, Sala L, Ballerini L (1980) Effects of modifications in position 4 of the chromophore or in position 4′ of the aminosugar, on the antitumor activity and toxicity of daunorubicin and doxorubicin. In: Crooke ST, Reich SD (eds) Anthracyclines: current status and new developments. Academic Press, New York, pp 404–430
Casazza AM, Bellini O, Savi G, Di Marco A (1981) Antitumor activity and cardiac toxicity of 4′-deoxydoxorubicin (4′-deoxyDX) in mice. Proc Am Assoc Cancer Res 22: 267
Cassinelli G, Di Matteo F, Forenza S, Ripamonti MC, Rivola G, Arcamone F, Di Marco A, Casazza AM, Soranzo C, Pratesi G (1980) New anthracycline glycoside from micromonospora II, isolation, characterization and biological properties. J Antibiot (Tokyo) 33: 1468
Di Marco A, Lenaz L, Casazza AM, Scarpinato BM (1972) (NSC-82151) against mouse mammary carcinoma. Cancer Chemother Rep 56: 153
Di Marco A, Casazza AM, Giuliani F, Pratesi G, Arcamone F, Bernardi L, Franchi G, Giardino P, Patelli B, Penco S (1978a) Synthesis and antitumor activity of 4-demethoxyadriamycin and 4-demethoxy-4′-epiadriamycin. Cancer Treat Rep 62: 375
Di Marco A, Casazza AM, Soranzo C, Pratesi G (1978b) Effect of various substitutions in position 1, 2, 3, and 4 of 4-demethoxydaunorubicin and 4-demethoxyadriamycin. Cancer Chemother Pharmacol 1: 249
Giuliana FC, Kaplan NO (1980) New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse. Cancer Res 40: 4682
Hamburger AW, Salmon SE (1977) Primary bioassay of human tumor stem cells. Science 197: 461
Salmon SE (ed) (1980) Cloning of human tumor stem cells. Alan R. Liss, New York
Salmon SE (1981) Applications of the human tumor stem cell assay in the development of anticancer therapy. In: Burchenal JH, Oettgen HF (eds) Cancer — Achievements, challenges and prospects for the 1980s. Grune & Stratton, New York, pp 33–44
Salmon SE, Hamburger AW, Soehnlen B, Durie BGM, Alberts DS, Moon TE (1978) Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. N Engl J Med 298: 1321
Salmon SE, Meyskens FL, Alberts DS, Soehnlen B, Young L (1981) New drugs in ovarian cancer and malignant melanoma: In vitro phase II screening with the human tumor clonogenic cell assay. Cancer Treat Rep 65: 1–12
Venditti J, Plowman M, Wolpert M (1981) report to Board of Scientific Counselors, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland
Villani F, Piccinini F, Favalli L (1980) Anthracycline analogs: correlation between calcium turnover in guinea pig atria and cardiotoxicity in humans. In: Nelson JD, Grossi C (eds) Current chemotherapy and infectious disease, vol II. American Society of Microbiology, Washington, pp 1696–1698
Von Hoff DD, Casper J, Bradley E, Jones D, Makuch R (1981) Association between human tumor colony forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med 70: 1027–1032
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Salmon, S.E., Liu, R.M. & Casazza, A.M. Evaluation of new-anthracycline analogs with the human tumor stem cell assay. Cancer Chemother. Pharmacol. 6, 103–109 (1981). https://doi.org/10.1007/BF00262325
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00262325